Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models

Brain

Volumn 138, Issue 5, 2015, Pages 1247-1262

  Wang, Qingshan ^a   Qian, Li ^a   Chen, Shih Heng ^a   Chu, Chun Hsien ^a   Wilson, Belinda ^a   Oyarzabal, Esteban ^a   Ali, Syed ^b   Robinson, Bonnie ^b   Rao, Deepa ^a   Hong, Jau Shyong ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b Natl Ctr Toxicological Res F   (United States)

Author keywords

microglia; NADPH oxidase; neuroinflammation; Parkinson's disease; superoxide

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DIPHENYLIODONIUM SALT; ENDOTOXIN; LIPOPOLYSACCHARIDE; CATION; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; LOW DRUG DOSE; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MICROGLIA; NERVE DEGENERATION; PATHOLOGY; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; ENZYME INHIBITORS; MICE, INBRED C57BL; MICROGLIA; NADPH OXIDASE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; ONIUM COMPOUNDS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84929657195     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv034     Document Type: Article

References (49)

1. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, et al. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 2008; 9: 686-96.
2. Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: A population-based case-control study. Eur J Neurol 2011; 18: 1336-42.
3. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
4. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
5. Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems. Trends Neurosci 2013; 36: 543-54.
6. Cannon JR, Greenamyre JT. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res 2010; 184: 17-33.
7. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005; 58: 963-7.
8. Czirr E, Wyss-Coray T. The immunology of neurodegeneration. J Clin Invest 2012; 122: 1156-63.
9. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29: 357-65.
10. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002; 81: 1285-97.
11. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003; 17: 1954-6.
12. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 2011; 119: 807-14.
13. Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci 2012; 33: 295-303.
14. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011; 31: 1081-92.
15. Gatley SJ, Martin JL. Some aspects of the pharmacology of diphenyleneiodonium, a bivalent iodine compound. Xenobiotica 1979; 9: 539-46.
16. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002; 34: 521-33.
17. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009; 24: 647-54.
18. Hirsch EC. How to improve neuroprotection in Parkinson's disease? Parkinsonism Relat Disord 2007; 13 (Suppl 3): S332-5.
19. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, et al. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 2008; 181: 7194-204.
20. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-9.
21. Lambeth JD, Krause KH, Clark RA. NOX enzymes as novel targets for drug development. Semin Immunopathol 2008; 30: 339-63.
22. Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006; 52: 33-8.
23. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS, et al. Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 2010; 133(Pt 3): 808-21.
24. Liu Y, Qin L, Wilson B, Wu X, Qian L, Granholm AC, et al. Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology 2008; 29: 864-70.
25. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-47.
26. Miesel R, Kurpisz M, Kroger H. Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free Radic Biol Med 1996; 20: 75-81.
27. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22: 123-44.
28. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010; 6: 193-201.
29. Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl 1): S207-9.
30. Qin L, Liu Y, Hong JS, Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 2013; 61: 855-68.
31. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004; 279: 1415-21.
32. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-62.
33. Quick KL, Dugan LL. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann Neurol 2001; 49: 627-35.
34. Rao DB, Little PB, Sills RC. Subsite awareness in neuropathology evaluation of national toxicology program (ntp) studies: A review of select neuroanatomical structures with their functional significance in rodents. Toxicol Pathol 2013; 42: 487-509.
35. Salawu F, Olokoba A, Danburam A. Current management of Parkinson's disease. Ann Afr Med 2010; 9: 55-61.
36. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26: 769-79.
37. Sato K, Kadiiska MB, Ghio AJ, Corbett J, Fann YC, Holland SM, et al. In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: A model for ARDS. FASEB J 2002; 16: 1713-20.
38. Streit WJ. Microglial response to brain injury: A brief synopsis. Toxicol Pathol 2000; 28: 28-30.
39. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001; 39: 167-74.
40. Vlessis AA, Bartos D, Muller P, Trunkey DD. Role of reactive O2 in phagocyte-induced hypermetabolism and pulmonary injury. J Appl Physiol (1985) 1995; 78: 112-6.
41. Wang Q, Chu CH, Oyarzabal E, Jiang L, Chen SH, Wilson B, et al. Subpicomolar diphenyleneiodonium inhibits microglial NADPH oxidase with high specificity and shows great potential as a therapeutic agent for neurodegenerative diseases. Glia 2014a; 62: 2034-43.
42. Wang Q, Chu CH, Qian L, Chen SH, Wilson B, Oyarzabal E, et al. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J Neurosci 2014b; 34: 12490-503.
43. Wang Q, Shin EJ, Nguyen XK, Li Q, Bach JH, Bing G, et al. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 2012; 9: 124.
44. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 6145-50.
45. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neurosci 2010; 167: 475-81.
46. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J Pharmacol Exp Ther 2007; 322: 913-22.
47. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF, et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 2004; 18: 589-91.
48. Zigmond MJ. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 1997; 4: 247-53.
49. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990; 13: 290-6.